Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 11/20 | 1.00 |
| ▸ | RARB | P10826 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404495 | 1.00 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL406794 | 1.00 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL407354 | 1.00 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL400817 | 1.00 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL14645634 | 1.00 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL403560 | 1.00 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL2278156 | 1.00 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL12487331 | 0.93 | GPR35 (0.87) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL10144291 | 0.89 | GPR35 (0.80) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL10144290 | 0.89 | GPR35 (0.80) | GPR35RARBMEN1ALDH1A1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595975-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | Corning Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | GPR35 1/4885RARB 717/4885MEN1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.